According to iX Biopharma latest financial reports the cash on hand of 42C is $5.03M, an decrease of -51.69% to 2022. At the end of 2022 company had $10.41M cash on hand. This amount reflects the liquid assets available to the company, which are crucial for its operational flexibility, investment opportunities, and overall financial security.
Year | Cash on Hand | Change |
---|---|---|
2023 | $5.03M | -51.69% |
2022 | $10.41M | 117.47% |
2021 | $4.79M | 9.57% |
2020 | $4.37M | -64.32% |
2019 | $12.25M | - |